



MGC Diagnostics Corporation
through its subsidiary Medical Graphics Corporation
350 Oak Grove Parkway
St. Paul, Minnesota USA, 55127-8599

MGC DIAGNOSTICS CORPORATION ADDS SLEEP APNEA DIAGNOSTIC PRODUCT THROUGH EXCLUSIVE DISTRIBUTION PARTNERSHIP WITH SLEEPVIRTUAL

SAINT PAUL, MN (May 13, 2014) —MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology leader, has entered into an exclusive distribution agreement with Neurovirtual USA Inc. under which MGC Diagnostics will market and distribute the SleepVirtual BWII PSG and BWIII PSG Diagnostic polysomnography systems in the United States and Canada.

The SleepVirtual products are used in the diagnosis and treatment of sleep apnea and sleep-related breathing disorders. Sleep apnea diagnosis is usually done at a sleep disorders unit within a hospital or at a sleep center.

The SleepVirtual BWII has a small, lightweight design and may be used as a stationary unit or a portable unit (fitting into a small briefcase), providing flexibility to use one device in several locations. The SleepVirtual BWIII PSG Plus is a larger device with combined sleep and neuro-diagnostics (EEG) capabilities.

Todd M. Austin, EVP Global Marketing, Engineering and Corporate Strategy of MGC Diagnostics, commented "Our agreement with SleepVirtual is an example of how MGC Diagnostics continues to execute strategic partnerships with "best in class" providers of technology serving adjacent cardiorespiratory diagnostic markets . Together with SleepVirtual, MGC Diagnostics is well positioned to provide diagnostic capabilities to physicians managing complex patients, including patients with both COPD (chronic obstructive pulmonary disease) and OSA (obstructive sleep apnea). Leveraging MGC Diagnostic's global sales, marketing, and support network provides our customers best-in-class access to cardiorespiratory healthcare professionals and their patients throughout the world."

Ed Faria, MBA, Chief Executive Officer of Neurovirtual, commented: "As a private company with limited resources, this agreement allows us to focus our efforts on product development and customer service, further developing our SleepVirtual product line and advancing our technology."

About Neurovirtual/SleepVirtual

For over 15 years, Neurovirtual has specialized in developing, manufacturing, marketing, and servicing high-technology medical devices used in Sleep Medicine and Neurology. Based in Doral, FL, Neurovirtual's mission is to provide high quality medical equipment at an affordable price and to assist in the diagnosis and treatment of Neurological and Sleep Disorders. Neurovirtual sells products in 40 countries, using a network of distributors supported by 5 local offices, located in the USA, Germany, Brazil, Mexico and Colombia. For more information about SleepVirtual, visit www.neurovirtual.com.



MGC Diagnostics Corporation
through its subsidiary Medical Graphics Corporation
350 Oak Grove Parkway
St. Paul, Minnesota USA, 55127-8599

About MGC Diagnostics

MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). MGC Diagnostics focus is on providing unmatched service and support, relentlessly making improvements, and anticipating and solving unmet needs. For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements

From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in federal securities laws. These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. In addition, these forward statements are subject to the Company's ability to negotiate and enter into a definitive acquisition agreement, complete the acquisition, and profitably integrate the Medisoft operations into a combined Company. For a list of additional factors, see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2013, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

Contact: Wesley W. Winnekins
MGC Diagnostics Corporation
Chief Financial Officer
(651) 484-4874

Joe Dorame, Robert Blum, Joe Diaz
Lytham Partners, LLC
(602) 889-9700
mgcd@lythampartners.com